共查询到7条相似文献,搜索用时 0 毫秒
1.
2.
3.
本文报道了环孢霉素-A滴眼剂的制备圾HPLC方法测定含量,3种批号含量分别为99.9%;临床应用77例,5种病种,有效率为83%。 相似文献
4.
OBJECTIVE: To evaluate the efficacy of topical 1% cyclosporin A (CsA), 0.1% dexamethasone or 1% CsA combined with 0.1% dexamethasone in preventing and treating immune rejection after penetrating keratoplasty (PKP). METHODS: Eighty-six eyes from 86 PKP patients were randomly divided into 3 groups: (1) Thirty-one eyes were treated with 1% CsA and dexamethasone for 3 months. (2) Twenty-nine eyes were treated with 1% CsA for 3 months; (3) Twenty-six eyes were treated with 0.1% dexamethasone for 3 months. The rejected eyes of postoperation were given with the dexamethasone injection under conjunctiva and increased the frequency of CsA and dexamethasone eye drops. All patients were followed up for 1 to approximately 2 years. RESULTS: There was a statistical difference in the 3 groups in the postoperative immune rejection which occurred in 5 out of 29 (17.3% ) eyes treated with 1% CsA, 7 out of 26 (26.9%) treated with 0.1% dexamathasone, and 3 out of 31 (9.7%) with 1% CsA and dexamethasone. The immune rejection after PKP occurred in 15 eyes and 13 eyes were cured by sub-conjunctiva injection of dexamethasone combined with eye drops of 1% CsA and 0. 1% dexamethasone. CONCLUSION: The efficacy of CsA combined with dexamethasone topically is better than that of 1% CsA or 0.1% dexamethasone alone in preventing rejection episodes. It is effective to cure the graft rejection after PKP with sub-conjunctiva injection of dexamethasone combined with the eye drop of 1% CsA and 0.1% dexamethasone. 相似文献
5.
目的:探讨环孢霉素A不同剂量对大鼠角膜移植免疫排斥反应的影响。方法:以Wistar大鼠为供体,Lewis大鼠为受体建立角膜移植实验模型。将33只Lewis大鼠(33眼)随机分为A、B、C3组,每组11只。A组术后肌注CsA【1mg,(kg·d)】,B组给予CsA【10mg/(kg·d)】,C组给予等量不含药物的PBS,每次100ul,3次/d,连续用药10d。术后判断植片排斥情况,比较3组角膜植片的平均存活时间和新生血管评分。术后10d,病理组织学检查角膜的结构变化,并进行T细胞增殖实验,观察各组间T细胞增殖情况。结果:A、B组植片发生排斥反应的时间明显延迟,A组植片平均存活时间为(12.5±0.43)d,B组为(58±18.79)d,C组为(9±0.45)d,3组比较差异有统计学意义(P〈0.01)。B组术后各时间点角膜新生血管的生长明显低于C组(P〈0.05)。A组与c组除第6天外,其余时间点无统计学意义。A、B组角膜植片中炎性细胞和新生血管较c组减少。角膜A、B组T细胞增殖量明显低于C组(P〈0.05)。结论:10mg/(kg·d)CsA能够有效抑制大鼠角膜移植术后免疫排斥的发生。 相似文献
6.
目的 :比较观察环孢霉素A(cyclosporinA ,CsA)、地塞米松和CsA联合地塞米松对穿透性角膜移植(penetratingkeratoplasty ,PKP)术后免疫排斥反应的防治效果。方法 :86例 (86眼 )PKP术后患者 ,随机分为 3组。①CsA组 ,2 9例 2 9眼 ,用 1%CsA溶液滴眼 ;②地塞米松组 :2 6例 2 6眼 ,用 0 .1%地塞米松溶液滴眼 ;③CsA联合地塞米松组 :31例 31眼 ,用 1%CsA和 0 .1%地塞米松溶液滴眼。 3组每日滴眼各 3~ 4次 ,均于术后 1月改为 2~ 3次 ,持续用药 3个月以上。对PKP术后发生植片免疫排斥反应者 ,予以结膜下注射地塞米松和增加 1%CsA及 0 .1%地塞米松滴眼液的滴眼频次 ,直至病情缓解。所有患者随访 1~ 2年。结果 :术后发生角膜免疫排斥反应共 15眼(17.4 % ) ,其中CsA组 5眼 (17.2 % ) ,地塞米松组 7眼 (2 6 .9% ) ,CsA联合地塞米松组 3眼 (9.7% )。后组与前 2组比较差异具有显著性 (P <0 .0 5 )。 15只发生排斥反应眼经治疗有 13眼得到有效控制。结论 :PKP术后应用 1%CsA联合 0 .1%地塞米松滴眼能更有效地减少植片免疫排斥反应发生率 ;结膜下注射地塞米松和增加CsA及地塞米松滴眼液的滴眼频次 ,能有效控制PKP术后所发生的免疫排斥反应 ,从而提高穿透性角膜移植的成功率。 相似文献